A complete analysis of the applicable groups and medication guidance of Mobotinib (Mobosetinib)

Mobocertinib is a new oral tyrosine kinase inhibitor, mainly targeting patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. This type of mutation is relatively rare in lung cancer patients, but traditional EGFR inhibitors have limited efficacy against this type of mutation. The emergence of mobotinib has brought new treatment options to these patients, especially for adult patients with NSCLC who have previously received platinum-based chemotherapy but whose disease has progressed.

For the applicable population, Mobotinib is mainly used to treat patients with non-small cell lung cancer who are positive for insertion mutations in EGFRexon20. These patients are usually resistant to other targeted drugs or have poor treatment effects. Patients need to confirm whether there is an EGFR exon 20 insertion mutation through genetic testing. Mobotinib can only be used after a clear diagnosis. The drug is particularly suitable for patients who have already received first-line chemotherapy and whose disease is still progressing, providing them with an effective follow-up treatment option.

In terms of medication guidance, Mobotinib is recommended to be administered orally, usually once a day, and the dosage is adjusted according to the doctor's recommendations and the patient's specific conditions. During the period of medication, liver and kidney function and blood routine should be monitored regularly, and possible side effects should be paid attention to, such as diarrhea, rash, stomatitis, fatigue, etc. Patients should strictly abide by medical instructions and avoid adjusting dosage or discontinuing medication on their own. In case of serious adverse reactions, you should seek medical treatment promptly and communicate with the doctor to adjust the treatment plan.

In addition, while taking Mobotinib, patients should pay attention to their diet and living habits, maintain a good daily routine, and enhance their body's immunity. Regular follow-up and imaging examinations are essential to evaluate the effectiveness of treatment and to detect drug-related side effects in a timely manner. In general, mobotinib provides a precise and effective treatment option for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. However, safe medication and scientific management are equally critical. Patients need to use medication rationally under the guidance of professional doctors to maximize the efficacy of the medication.

References：https://en.wikipedia.org/wiki/Mobocertinib